Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...

It's not fully appreciated how much of an impact sickle cell disease can have on a person's mental health, writes columnist.

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

CTX-131 is under clinical development by CRISPR Therapeutics and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II drugs for T-Cell Lymphomas have a 29% phase transition ...

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

More than 500,000 babies were tested for sickle cell disease in Catalonia’s newborn screening program, with 160 cases ...

Pediatric patients with sickle cell anemia and a history of abnormal cerebral artery velocities had reduced hospitalizations ...

Mr Ibrahim Turyasingura and his wife Ms Hajira Kataike are raising a four-year-old daughter who has Sickle Cell Disease. The couple says despite their awareness of sickle cell, they did not ...

After an allogeneic stem cell transplant, a recipient’s body faces a daunting task: rebuilding the person’s blood-forming and ...